Cesca Therapeutics (NASDAQ: KOOL) is engaged in the research, development and commercialization of cellular therapeutics and devices for use in regenerative medicine and hematological and oncological applications. The company’s technologies address cellular therapeutics, medical/diagnostic devices, cell manufacturing and cryopreservation. Along with its proprietary automated devices for concentration of therapeutic stem cells from blood, Cesca is currently undertaking an FDA-approved pivotal trial to treat late stage critical limb ischemia (CLI) with its SurgWerks™ Platform for the delivery of regenerative cell therapy for vascular disease and orthopedic indications. For more information, visit the company’s website at www.cescatherapeutics.com